Intravenous Thrombolysis in Patients on Direct Oral Anticoagulants: Analysis of the Get With The Guidelines Stroke Registry
Authors:
- Shadi YaghiSYShadi Yaghi
- Liqi ShuLSLiqi Shu
- Eva A. MistryEMEva A. Mistry
- Opeolu AdeoyeOAOpeolu Adeoye
- Lee SchwammLSLee Schwamm
- Steven MesseSMSteven Messe
- Mitchell S. V. ElkindMEMitchell S. V. Elkind
- Malik GhannamMGMalik Ghannam
- Adam de HavenonAHAdam de Havenon
- Karen FurieKFKaren Furie
- Ying XianYXYing Xian
- Christopher StreibCSChristopher Streib
Open Access
- 6 January 2026
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e044321
Abstract
Background: Intravenous thrombolysis for acute ischemic stroke (AIS) is a proven effective treatment. Whether thrombolysis in patients with AIS with recent direct oral anticoagulant (DOAC) use is safe and efficacious is not well established. We aimed to compare outcomes of patients with AIS and recent DOAC use who received thrombolysis to those otherwise eligible but excluded due to recent DOAC use. Methods: This study included patients for the GWTG (Get With The Guidelines) registry with a diagnosis of AIS within 4.5 hours from last known normal, on a DOAC, and either (1) received intravenous thrombolysis, or (2) were excluded from thrombolysis with coagulopathy being the only reason for exclusion. We used univariate and adjusted binary logistic regression models with clustering by site to compare the 2 groups’ functional status (ambulation on discharge and discharge disposition) and reported rates of safety outcomes in the thrombolysis group. Results: The study sample included 48 907 patients with AIS using a DOAC; 4702 received thrombolysis and 44 205 did not. In adjusted logistic regression models, patients with recent DOAC use receiving thrombolysis had increased odds of independent ambulation at discharge (odds ratio [OR], 1.35[ 95% CI, 1.21–1.50]) and home discharge (OR, 1.33 [95% CI, 1.22–1.46]). The rate of symptomatic intracranial hemorrhage with intravenous thrombolysis in patients with recent DOAC use was 3.5% (95% CI, 3.0%–4.1%). Conclusions: In this study, intravenous thrombolysis was associated with improved functional outcomes in patients with recent DOAC use and appeared safe. Given the study limitations, findings require validation by prospective trials.Keywords
This publication has 23 references indexed in Scilit:
- Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral AnticoagulantsJAMA Neurology, 2023
- Association of Recent Use of Non–Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With AlteplaseJAMA, 2022
- Predictive value of discharge destination for 90-day outcomes among ischemic stroke patients eligible for endovascular treatment: Post-hoc analysis of DEFUSE 3Journal of Stroke and Cerebrovascular Diseases, 2020
- Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profilesDrug Metabolism and Pharmacokinetics, 2020
- Rivaroxaban with or without Aspirin in Stable Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Low risk of ICH after reperfusion therapy in acute stroke patients treated with direct oral anti-coagulantJournal of the Neurological Sciences, 2017
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- Discharge Destination as a Surrogate for Modified Rankin Scale Defined Outcomes at 3- and 12-Months Poststroke Among Stroke SurvivorsArchives of Physical Medicine and Rehabilitation, 2012
- Number Needed to Treat Estimates Incorporating Effects Over the Entire Range of Clinical OutcomesArchives of Neurology, 2004
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995